Webinars

View our webinar on 'Harnessing A Three-Organ MPS Model to Assess Drug and Chemical Safety'

View our webinar on 'Recovery Insight: Prospective Collection of Human Neurological Tissues'

'Bridging Species: IVIVE Approaches to Thyroid Hormone Clearance in Human and Rat Hepatocytes'

View our webinar on 'Improving Human Safety Decisions with a Functional In Vitro Thyroid Model'

Learn how our assays help predict dermal absorption of compounds and support safer, more effective product development.

Learn about complementary findings that address two key translational gaps using TruVivo®, LifeNet Health’s all-human 2D+ hepatic system.

Join us for an insightful webinar where we will discuss some of the fundamentals of liver biology and physiologically-relevant hepatocyte culture systems. 

View this insightful fireside chat between Chief Scientists from CN Bio and LifeNet Health. 

Gain insights into how TruVivo® enhances the predictive accuracy of DDI assessments, potentially reducing the need for extensive clinical interaction studies and accelerating the drug development process.

Learn the fundamentals of hepatocyte culture and the essential role of non-parenchymal cells in maintaining liver function in vitro. 

Learn how TruVivo, a novel human hepatocyte model, improves metabolic clearance predictions for aldehyde oxidase substrates in drug development.

Explore how TruVivo, a pioneering all-human liver system, offers a new way to study diseases like MAFLD. In this webinar, Jessica Weaver, PhD, describes how TruVivo enables the long-term culture of primary human hepatocytes derived from diseased livers, retaining key features of MAFLD, including steatosis, inflammation, and fibrosis markers. The system was also used to investigate Obeticholic acid’s (OCA) impact of lipogenesis and bile acid transport.

This webinar explores how TruVivo ranks the toxicity of several reference compounds representing multiple mechanisms of action. Edward LeCluyse, PhD, also expands on how the addition of human Kupffer cells in the TruVivo system successfully captures inflammatory and fibrogenic responses that lead to enhanced compound toxicity.

Bud Brame and Jeff Thomas, from LifeNet Health LifeSciences discuss how LifeNet Health ensures the highest standards in the recovery, transport, and handling of human biospecimens for research and how these critical steps are essential to the quality of tissue used in pre-clinical research studies and greatly impacts the quality of data generated.

Sharon Presnell, PhD, LifeNet Health LifeSciences Vice President of Product Development, discusses the dynamic landscape of biomedical research and how choosing the right cells for your experiment is a fundamental step in achieving meaningful and reproducible results. Careful consideration is vital to success, whether your work involves drug discovery, disease modeling, cytotoxicity assays, or studying cellular processes.

Diane Ramsden, PhD, from AstraZeneca, presents data from her evaluation of TruVivo as a potential tool for investigating mechanistic DMPK, including drug-drug interaction potential and translational risk assessment.

Ed LeCluyse, PhD, Chief Scientist LifeNet Health LifeSciences, reveals application data generated by leading pharmaceutical partners, demonstrating the use of TruVivo for ADME/DMPK and disease modeling applications. Dr LeCluyse also shares a sneak peek of where TruVivo stands regarding the inclusion of human Kupffer cells and preclinical species.

Emerging toxicology methods can help researchers move away from traditional animal testing. Industry leader James McKim, PhD, will provide information about how to select the best platform – including the need for integrated organ models. 

Ed LeCluyse, PhD, LifeNet Health LifeSciences, reveals the convenient all-human hepatocyte triculture model, highlighting improvements in hepatocyte performance compared to traditional monoculture.

Ed LeCluyse, PhD, and Paul Gallant, BA, of LifeNet Health provide an inside look at a novel all-human hepatic triculture system developed by LifeNet Health LifeSciences.

Jessica Weaver, PhD, Research and Product Development Scientist at LifeNet Health, reviews data from our new hepatic cell-based co-culture model which is comprised of primary human hepatocytes with human feeder cells, all derived 100% from donated human tissue. 

Learn about how multi-organ microphysiological systems are being used as an investigative tool in medical research as Martin Trapecar, PhD, explains his work to investigate the fundamental origins of immunometabolic diseases.

Nicky Hewitt, PhD, a consultant with Cosmetics Europe, explains how her skin-liver-thyroid MPS model is being used to support animal-free cosmetics testing.

Microphysiology systems offer promising new alternatives for disease investigations and safety testing. Learn more about this leading-edge technology in our webinar featuring Lawrence Vernetti, PhD, of the University of Pittsburgh.

Eda Rogers, PhD, A Research & Discovery Scientist at LifeNet Health, shares her research into a new approach using an in vitro 3D human thyroid model. This project, under development with the United States Environmental Protection Agency, represents the first human thyroid model system to be considered for the Endocrine Disruptor Screening Program.

Learn about the latest efforts to gain insight into human diseases using microphysiological systems, featuring Linda Griffith, PhD.

Mary Jane Cunningham, PhD, LifeNet Health LifeSciences Director for Clinical Applications and Services, discusses how the genotype for primary human hepatocytes may be essential to your research and testing.

Chandan Guha, PhD, of the Albert Einstein College of Medicine presents his research focusing on the adverse effects of irradiation on normal tissue.

Program Director Jeffrey Thomas describes the industry-leading recovery protocols and enhanced donor family consent process he helped develop for LifeNet Health LifeSciences.

Donald Tweedie, PhD, and Edward LeCluyse, PhD, share lessons learned over a combined 70 years in drug development and research on alternative drug metabolism and toxicological methods.

Donald Tweedie, PhD and Ed LeCluyse, PhD continue their former discussion on the challenges and opportunities with using primary human hepatocytes in drug development. 

Ed LeCluyse, PhD, explains how LifeNet Health LifeSciences' unique, vertically integrated process has raised the bar for quality standards to enable access to high-quality human tissues and cells for research.

Daniel Perl, PhD, presents his research aimed at understanding the long-term consequences of traumatic brain injury (TBI) among military personnel. Dr. Perl is the Director of the Brain Tissue Repository at the Uniformed Services University of the Health Sciences/Department of Defense in Bethesda, Md.

Scott Jewel, PhD, and Galen Hostetter, PhD, both of the Van Andel Research Institute, share their best practices for the management and use of biospecimens, specifically around the identification of variables on biospecimen quality and processing that can directly impact research results.

Eda Rogers, PhD, Research and Development Scientist at LifeNet Health, shares details of how she and other LifeNet Health scientists have isolated, cryopreserved, and characterized primary human thyrocytes,

Laura Siminoff, PhD, Dean at the College of Public Health at Temple University, discusses best practices for communicating and obtaining consent from donor families based on experience from the Genotyping-Tissue Expression Project (GTEx).

Alan Grodzinsky, ScD, of the Massachusetts Institute of Technology shares exciting details on a human, in vitro model being co-developed by MIT, the NIH National Center for Advancing Translational Sciences, and the National Aeronautics and Space Administration.

Mary Jane Cunningham, PhD, explains how the genotyping of primary human hepatocytes may be essential to your experimental design and how knowing the donor’s genotype could help with stratifying hepatocyte lots used in drug discovery and development assays.

Ed LeCluyse, PhD, Chief Scientist of LifeNet Health’s Institute of Regenerative Medicine, presents on the criticality of utilizing primary human hepatocytes in pre-clinical drug development.

Chris Willey, MD, PhD, shares how 3D human microtumors are being established as a human-based diagnostic screening method to optimize chemotherapeutic regimens.

Only LifeNet Health LifeSciences controls every step of a tissue's journey from donor to lab while serving researchers needs from early-stage discovery to pre-clinical drug-safety evaluation.

Ed LeCluyse, PhD, Chief Scientist of LifeNet Health’s Institute of Regenerative Medicine, describes how liver non-parenchymal cells (NPCs) — including stellate, Kupffer, and liver endothelial cells — play a role in the progression of liver toxicity and disease.

Dr. Ed LeCluyse from LifeNet Health LifeSciences describes the importance of using data to identify the right hepatocyte lots for your specific applications, with insight into emerging trends in hepatocyte characterization.